Publications by authors named "William Barchuk"

Claim this Profile
C
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.
Michael Trauner, Cynthia Levy, Atsushi Tanaka, Zachary Goodman, Douglas Thorburn, William T Barchuk

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
Sunil K Srivastava, Timothy R Watkins, Quan Dong Nguyen, Sumit Sharma, David K Scales, William T Barchuk

JAMA Ophthalmol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Cynthia Levy, Stephen Caldwell, Parvez Mantry, Velimir Luketic, Charles S Landis, William T Barchuk

Clin Transl Gastroenterol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.
Douglas Thorburn, Diana J Leeming, William T Barchuk, Ya Wang, Xiaomin Lu

Hepatol Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Elijah J Weber, Islam R Younis, Lulu Wang, Deqing Xiao, William T Barchuk

Clin Pharmacol Drug Dev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Walter P Maksymowych, Mikkel Østergaard, Robert Landewé, William Barchuk, Ke Liu

Rheumatology (Oxford)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
Walter P Maksymowych, Mikkel Østergaard, Robert Landewé, William Barchuk, Ke Liu

Rheumatology (Oxford)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study.
Mark C Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, William Barchuk

J Rheumatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toreforant, an orally active histamine H-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study.
David L Boyle, Samuel E DePrimo, Cesar Calderon, Dion Chen, Paul J Dunford, William Barchuk

Inflamm Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, William Barchuk

Lancet· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion.
William T Barchuk, Anne Marie Salapatek, Tingting Ge, Pina D'Angelo, Xuejun Liu

J Allergy Clin Immunol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
Edward A Panacek, John C Marshall, Timothy E Albertson, David H Johnson, Steven Johnson, William T Barchuk

Crit Care Med· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial.
Rodger D MacArthur, Mark Miller, Timothy Albertson, Edward Panacek, David Johnson, William Barchuk

Clin Infect Dis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis